Regeneron licensed a weight loss drug and revealed study data for a pair of muscle-preserving medicines. Elsewhere, two neuroscience biotechs cut deals and Bluebird officially went private.

One clinical trial is assessing whether semaglutide, used in weight loss drugs, could slow the progression of dementia ...

The National Institute for Health and Care Excellence is taking more evidence and is expected to announce its decision in the ...

Are you tired of boring dieting and gruesome workouts? Then, medical weight loss treatment can be a solution for you. But ...

Participants received weekly injections of the highest tolerated doses of Zepbound, either 10 milligrams or 15 milligrams, or Wegovy, 1.7 milligrams or 2.4 milligrams. By the end of the trial ...

The company is preparing a Phase 3 trial of enobosarm with a novel formulation that could extend its patent life.

Drugmakers are offering the blockbuster medications at steep discounts to people willing to pay out of pocket.

It is now illegal to publish or threaten to publish real or AI-generated intimate images of a person without their consent. Tech sites and companies also must take down such images within 48 hours of ...

Share on Pinterest Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly. Shelby Knowles/Bloomberg/Getty Images Zepbound outperformed ...

FRANKFURT, Germany (AP) — Danish pharmaceutical company Novo Nordisk A/S, maker of blockbuster weight loss drug Wegovy, said Friday its CEO was stepping down by “mutual agreement” with the ...

Karen Read is facing second-degree murder charges in the January 2022 death of her boyfriend, Boston police officer John O’Keefe. Read pleaded not guilty to allegedly ramming O’Keefe with ...